The Economic Burden of Chronic Graft-Versus-Host Disease: A Resource Utilization Study Among Adult Recipients of Matched Sibling Donor and Umbilical Cord Blood Hematopoietic Cell Transplantation  by Sandhu, K.S. et al.
Poster Session II S345from 38-96 mg/kg/day. Total MPA Css concentrations ranged
between 1.1-3.9 mcg/mL (mean 2.17 6 0.76 mcg/mL). Total
MPA steady-state clearance (CLss) values ranged between 7.8-
28.6 mL/min/kg. Therapeutic total MPA Css levels were main-
tained in these patients for a duration of 10-30 days. Patients tol-
erated the infusion well and no infusion-related reactions or other
adverse events occurred.
In conclusion, we show that continuous infusion of MMF is
safe and feasible, and successfully achieves and maintains tar-
geted steady-state concentrations of MPA. We have extended
our pilot protocol in order to study the clinical impact and
pharmacokinetics of a continuous infusion of MMF for GVHD
prophylaxis on a larger and more diverse pediatric BMT popula-
tion in our institution.534
DYNAMICS OF DONOR T CELL ACTIVATION DURING EARLY PHASE OF
GRAFT VERSUS HOST DISEASE (GVHD): DONOR ANTIGEN PRESENTING
CELLS CAN ACTIVATE ALLOGENEIC T CELLS
Sadeghi, B.1,2, Al-Hashmi, S.1,2, Hassan, Z.1,2,3, Hassan,M.1,2 1Karolin-
ska Institutet, Stockholm, Sweden; 2Karolinska University Hospital Hud-
dinge, Stockholm, Sweden; 3Karolinska University Hospital Huddinge,
Stockholm, Sweden
Graft-versus-host disease (GVHD) is a major complication to he-
matopoietic stem cell transplantation (HSCT). The role of host an-
tigen presenting cells in the activation of donor T-cells has been
reported previously. In the present investigation we tracked host
and donor immune cells in a chronological approach to determine
phenotypical and biological activation patterns during early stages
of GVHD.
Female BALB/c mice were conditioned using busulfan and
cyclophosphamide and transplanted using either male C57BL/6
(allogeneic) or BALB/c (syngeneic) donors. Recipient mice were
killed at day 0,+1,+3,+5,+7 and +21 post BMT; spleen and BM
were assessed for phenotype and function of immune cells. Serum
cytokines were measured and histopathology and immunohisto-
chemistry examinations were carried out to confirm emergence
of GVHD.
GVHD occurred 7 days after allogeneic BMT. Donor dendritic
cells (DCs) significantly expanded and matured early after allo-
BMT (day+3) compared to that observed for host DCs expansion.
T-cells repopulation was similar in both allogeneic and syngeneic
group until day+3. However, donor CD8+ cell expansion, five days
after BMT was 230% compared to that observed in control. IL2,
IFN-gamma and TNF-alfa were at the highest level at day +5 which
were compatible with T-cell activation. Upon activation most of
na€ıve T-cells gain effector-memory phenotype and migrated from
the spleen to periphery.
Tracking of host versus donor immune cell at early phase of
GVHD have shown that donor DCs has essential role in the activa-
tion of donor allogeneic T-lymphocyte. Moreover, during activation
phase of T-cells in the spleen donor na€ıve cells gain effector-memory
phenotype and initiate GVHD.Table 1. Resource utilizatiom associated with CGVHD in first 2 yea
Characteristic MRD
N 29
Median outpatient visits (range) 49 (13-236) days
CMV infection 11 (38%)
Fungal infection 5 (17%)
Median IVIG infusions (range) 6 (3-16)
Median RBC transfusion (range) 14 (2-31)
Median platelet transfusion (range) 14 (4-168)
Total hospitalizations* 59
Median hospitalizations/patient (range) 3 (1-8)
Median hospital stay/admit (range) 18 (1-139)
*Hospitalizations occured in 18 (62%) MRD, 15 (68%) UCB and 8 (18%) contr535
IS IT IMPORTANT TO PERFORM LIVER BIOPSY AFTER ALLOGENEIC
TRANSPLANTATION?
Zak, P., Zavrelova, A., Cermanova, M., Jebavy, L., Belohlavkova, P.
Charles University, Faculty of Medicine and University Hospital, Hradec
Kralove, Czech Republic
Purpose: to evaluate how often was liver impairment caused due to
graft versus host disease after allogeneic transplantation.
Methods: From year 2004 to 2007 we performed liver biopsy in 17
patients (pts) because of the liver impairment after allogeneic stem
cell transplantation. The biopsy was performed in each patient every
time, we could not state the diagnosis from blood tests for sure.
We confirmed GVHD etiology just in 11pts (65%). 4 pts was di-
agnosed with toxic liver impairment, probably due to wide range of
medication. 1 patient was diagnosed with sinusoidal obstructive syn-
drome and in 1 case we proved EBV affection in combination with
autoimune hepatitis. There was no liver failure or progression of
liver function test in 6 pts, which we did not treat as GVHD accord-
ing to the biosy finding. As for liver function testing (bil, ALT, AST,
ALP, GMT) we did not find any important diference in this two co-
hort of pts. Pts with GVHD and other had nearly simmilar labora-
tory results in the time of biopsy.
It was interesting, that in histology examination we proved se-
vere liver hemosiderosis in 8pts (47%) and moderate liver hemosi-
derosis in 5pts (29%). In 6 pts we were also able to evaluate iron
storage in liver tissue, it was increased in each case, in some cases
there was very severe iron overload (range 2860- 11310 mikrog/g
with median 5134 mikrog/g). It corelated with serum ferritin level,
wchich was in range from 1930- 23123 mmol/kg with median
6256mmol/kg.
There was no complication after liver biopsy. In most cases we
performed classical transparietal biopsy. When transjugular biopsy
was performed, there was often no bile duct in the specimen of liver,
and as this is really important for right diagnosis, we had to do re-
biopsy in some cases.
Conclusion:we conclude, that after allogeneic transplantation is re-
ally important to do the liver biopsy and not to treat pts with immu-
nosupression without histological confirmation. It is also very
important to evaluate the liver storage of iron, because most patient
is heavy overload.
The study was supported by Research project of the Ministry of
Health of the Czech republic (MZO 00179906).536
THE ECONOMIC BURDEN OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A
RESOURCE UTILIZATION STUDY AMONG ADULT RECIPIENTS OF
MATCHED SIBLING DONOR AND UMBILICAL CORD BLOOD HEMATOPOI-
ETIC CELL TRANSPLANTATION
Sandhu, K.S., Arora, M., Alam, N., Burns, L.J., Weisdorf, D.J.,
Majhail, N.S. University of Minnesota, Minneapolis, MN
Chronic graft-versus-host disease (CGVHD) can impair quality
of life and is associated with significant morbidity and mortality
among allogeneic hematopoietic cell transplant (HCT) recipients.rs post-HCT
UCB Controls
22 45
37 (10-121) days 20 (4-90) days
8 (36%) 6 (13%)
3 (14%) 0
5 (3-14) 1 (1-10)
5 (1-30) 1 (1-3)
7 (1-95) 1 (1-19)
56 16
3 (1-12) 1 (1-9)
25 (4-176) 4 (1-69)
ols.
S346 Poster Session IIHowever, its costs and economic burden have not been well
described. Umbilical cord blood (UCB) transplantation is an
alternative donor source that has been reported to have lower
risks of CGVHD compared to matched related donor (MRD)
and unrelated donor transplantation. We conducted a single cen-
ter retrospective analysis to describe resource utilization associ-
ated with CGVHD. We also compared resources used by
recipients of UCB and MRD HCT. We assembled a cohort of
adult patients ($ 18 years) who received an allogeneic HCT at
our center from 2005-2007, had survived for at least 100 days
post-transplant and had a diagnosis of CGVHD. From the 83 pa-
tients (MRD 42. UCB 41) who met our criteria, we limited our
study to patients who had received all their care at our center
through 2 years post-HCT, relapse or death, which ever occurred
earlier. Our final cohort included 51 patients (MRD 29, UCB 22).
For both donor sources, included and excluded patients had com-
parable NIH severity, type and onset of CGVHD. For compari-
son purposes, we randomly selected a group of 45 controls who
met the same criteria as cases but had no CGVHD. Controls
were matched to cases by donor source and duration of followup
after HCT. For MRD and UCB recipients, median time to onset
of CGVHD was 175 and 144 days (P 5 0.73) and 55% and 59%
presented with overlap syndrome (P 5 0.78), respectively. Over-
all, 7%, 72% & 21% MRD and 27%, 65% & 5% UCB had
NIH graded mild, moderate and severe CGVHD (P 5 0.06).
Table 1 shows utilization of various resources among patients
with CGVHD and controls. There were similar patterns of re-
source utilization with respect to number of outpatient visits, hos-
pitalizations, and duration of hospital stay among UCB and MRD
recipients with CGVHD. However, a larger number of UCB re-
cipients with CGVHD were excluded because of receipt of care
elsewhere. Patients with chronic GVHD utilize extensive health
system resources. More research is needed to better understand
the costs of CGVHD to patients, centers and the health care
system and to determine if the lower incidence and severity of
CGVHD with UCB leads to long-term resource savings com-
pared to other graft sources.537
COMPOUND CHIMERISM POST-BONE MARROWAND LIVER TRANSPLAN-
TATION IN A PATIENT WITH SWACHMAN DIAMOND SYNDROME
Eagar, T.N.1,2, Diliogluo, S.1, Aung, F.4, Burns, K.1, McLin, V.3,
Leung, K.S.3, Land, G.1 1The Methodist Hospital, Houston, TX; 2The
University of Texas Southwestern Medical Center, Dallas, TX; 3MD An-
derson Cancer Center, Houston, TX; 4Texas Children’s Hospital, Houston,
TX
Shwachman Diamond Syndrome (SDS) is a rare autosomal reces-
sive disorder with a varied clinical presentation of developmental,
metabolic and hematopoetic defects. Bone marrow transplantation
(BMT) is an accepted therapy to correct the potentially fatal compli-
cations of bone marrow failure, granulocytopenia and thrombocyto-
penia that are associated with SDS.
The subject of this report is a 10 year old girl diagnosed with SDS.
After a prolonged history of life-threatening infections and throm-
bocytopenia, BMT was pursued. Following myeloablative therapy,
the patient received a BMT from a 9/10 matched unrelated donor
(MUD). Complete engraftment was noted at two weeks by short tan-
dem repeat (STR) analysis of the mononuclear cells (MNC) and
granulocytes. The clinical course over the next year was complicated
by multi-organ graft versus host disease (GVHD) requiring liver
transplantation from a living related donor.Within 6months the pa-
tient was re-hospitalized with recurrent GVHD. STR analysis iden-
tified the presence of MNC derived from the solid organ transplant.
Regular monitoring of the engraftment by STR revealed that the
solid organ transplant-derived cells rapidly and selectively reconsti-
tuted the T cell compartment of the peripheral blood. Surprisingly,
the granulocyte and B cells were derived from the HSC donor. Fol-
lowing a complicated course of bone marrow aplasia, thrombocyto-
penia, sepsis and renal insufficiency the patient succumbed to
GVHD.
GVHD following solid organ transplantation is relatively uncom-
mon; however, the effects can be devastating. Here we present a casewhere passenger T cells from a solid organ transplant elicited
GVHD. These results demonstrate that the solid organ-derived T
cells were able to mount an effective immune response against the
patient and the HSC donor resulting in renal failure and bone
marrow aplasia, respectively. These results highlight the necessity
of determining compatibility between all cell and tissue types in-
volved in complex transplantation procedures.538
RETROSPECTIVE, SINGLE CENTER STUDY OF SMART PORT CT
IMPLANTED CATHETERS (VORTEX PORT) FOR POST TRANSPLANT
EXTRACORPOREAL PHOTOPHERESIS FOR TREATMENT OF STEROID
REFRACTORY GRAFT-VS-HOST DISEASE
Candler, K.S.1, Anderson, J.2, Edmiston, W.1, Roberts, C.H.1,
Lamberta, J.1, Roseff, S.2, Clark, W.1, Toor, A.A.1, McCarty, J.M.1,
Chung, H.M.1 1Virginia Commonwealth University, Richmond, VA;
2Virginia Commonwealth University, Richmond, VA
Graft versus host disease (GVHD) is a major cause of morbidity
and mortality after allogeneic hematopoietic cell transplant
(HCT). Extracorporeal photopheresis (ECP) has been used success-
fully in the treatment of steroid refractory GVHD. Our center first
used ECP for GVHD in 1999. Our protocol for treatment of cuta-
neous GVHD is ECP two days per week every other week for three
months then reevaluate. If GVHD is improving, the frequency of
treatment would be reduced to two days per month. For visceral
GVHD, ECP treatment would be given three days per week every
other week for three months and then reassess and taper as above.
We currently use vortex ports (AngioDynamics, Latham, NY) for
long term access in our HCT patients and we hypothesize that it is
possible to perform ECP using vortex ports in patients with steroid
refractory GVHD and that the use of the port instead of external
catheters or venopuncture will improve quality of life for these
patients.
Patients who received at least one ECP treatment for treatment of
steroid refractory GVHD at our center between 1/1/07 and 9/30/10
were included (n5 47). During that time our center performed 1632
ECP procedures for treatment of GVHD including 552 procedures
after vortex port placement in 19 patients. Fifteen patients completed
100% of their ECP procedures with the vortex port after it was
placed. These patients had a total of 400 procedures with a range
of 6-51 procedures and a mean of 26.7 per patient. Four patients
had some of their procedures done with the port but required an-
other access method for 19 procedures. These patients had a total
of 133 procedures with a range of 27-36 and a mean 33.25 per pa-
tient. Of the patients that did not use the vortex port 100% of the
time, one had an uncomplicated line infection, one preferred IV ac-
cess to port use, one had anatomic issues with port placement, and
one had access to the port impaired by scleroderma. Overall, 97%
(533/552) of ECP procedures performed in patients with a vortex
port were completed using the port. Therefore, we conclude that
the use of the vortex port for ECP patients with steroid refractory
GVHD is feasible. Future studies are needed to evaluate infection
rate, bleeding risk, and quality of life in these patients compared
with those receiving ECP with external catheters or venopuncture
particularly in patients with sclerodermatous cutaneous GVHD.539
EARLY POST-TRANSPLANTATION FEBRILE EPISODES ARE ASSOCIATED
WITH INCREASED RISK FOR ACUTE GRAFT-VERSUS-HOST DISEASE
Ram, R.1, Paul, M.2, Gafter-Gvili, A.1, Hershkovitz, K.1, Israeli, M.1,
Peck, A.1, Raanani, P.1, Shpilberg, O.1, Yeshurun, M.1 1Rabin Medical
Center and Sackler School of Medicine, Tel Aviv University, Petah-Tikva,
Israel; 2Rabin Medical Center and Sackler School of Medicine,, Petah-
Tikva, Israel
Acute graft-versus-host disease (aGVHD) has remained a signifi-
cant cause of non-relapse mortality after allogeneic hematopoietic
cell transplantation (HCT). The conditions favoring the develop-
ment of aGVHD are thought to occur in the earliest phases of
